UPDATE: Morgan Stanley Downgrades Moderna (MRNA) to Equalweight

(updating comment)

Morgan Stanley analyst Matthew Harrison downgraded Moderna (NASDAQ: MRNA) from Overweight to Equalweight with a price target of $150.00.

The analyst comments "While we expect Moderna to be a more valuable company over a multiple year period, we expect near-term valuation to be dominated by COVID-19 revenues where expectations are already high. We expect vaccines, rare diseases and oncology
to be major opportunities for mRNA."

For an analyst ratings summary and ratings history on Moderna click here. For more ratings news on Moderna click here.

Shares of Moderna closed at $147.22 yesterday.

You May Also Be Interested In

• Wolfe Research Downgrades T-Mobile (TMUS) to Peerperform
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Powell Industries (POWL) PT Lowered to $235 at Cantor Fitzgerald